194 related articles for article (PubMed ID: 32207686)
1. Characterising a healthy adult with a rare HAO1 knockout to support a therapeutic strategy for primary hyperoxaluria.
McGregor TL; Hunt KA; Yee E; Mason D; Nioi P; Ticau S; Pelosi M; Loken PR; Finer S; Lawlor DA; Fauman EB; Huang QQ; Griffiths CJ; MacArthur DG; Trembath RC; Oglesbee D; Lieske JC; Erbe DV; Wright J; van Heel DA
Elife; 2020 Mar; 9():. PubMed ID: 32207686
[TBL] [Abstract][Full Text] [Related]
2. Lumasiran: First Approval.
Scott LJ; Keam SJ
Drugs; 2021 Feb; 81(2):277-282. PubMed ID: 33405070
[TBL] [Abstract][Full Text] [Related]
3. An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Liebow A; Li X; Racie T; Hettinger J; Bettencourt BR; Najafian N; Haslett P; Fitzgerald K; Holmes RP; Erbe D; Querbes W; Knight J
J Am Soc Nephrol; 2017 Feb; 28(2):494-503. PubMed ID: 27432743
[TBL] [Abstract][Full Text] [Related]
4. Glycolate oxidase deficiency in a patient with congenital hyperinsulinism and unexplained hyperoxaluria.
Clifford-Mobley O; Rumsby G; Kanodia S; Didi M; Holt R; Senniappan S
Pediatr Nephrol; 2017 Nov; 32(11):2159-2163. PubMed ID: 28752386
[TBL] [Abstract][Full Text] [Related]
5. Phase 1/2 Study of Lumasiran for Treatment of Primary Hyperoxaluria Type 1: A Placebo-Controlled Randomized Clinical Trial.
Frishberg Y; Deschênes G; Groothoff JW; Hulton SA; Magen D; Harambat J; Van't Hoff WG; Lorch U; Milliner DS; Lieske JC; Haslett P; Garg PP; Vaishnaw AK; Talamudupula S; Lu J; Habtemariam BA; Erbe DV; McGregor TL; Cochat P;
Clin J Am Soc Nephrol; 2021 Jul; 16(7):1025-1036. PubMed ID: 33985991
[TBL] [Abstract][Full Text] [Related]
6. Mutations in HAO1 encoding glycolate oxidase cause isolated glycolic aciduria.
Frishberg Y; Zeharia A; Lyakhovetsky R; Bargal R; Belostotsky R
J Med Genet; 2014 Aug; 51(8):526-9. PubMed ID: 24996905
[TBL] [Abstract][Full Text] [Related]
7. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF; Frishberg Y; Hulton SA; Koren MJ; O'Riordan WD; Cochat P; Deschênes G; Shasha-Lavsky H; Saland JM; Van't Hoff WG; Fuster DG; Magen D; Moochhala SH; Schalk G; Simkova E; Groothoff JW; Sas DJ; Meliambro KA; Lu J; Sweetser MT; Garg PP; Vaishnaw AK; Gansner JM; McGregor TL; Lieske JC;
N Engl J Med; 2021 Apr; 384(13):1216-1226. PubMed ID: 33789010
[TBL] [Abstract][Full Text] [Related]
8. Glycolate Oxidase Is a Safe and Efficient Target for Substrate Reduction Therapy in a Mouse Model of Primary Hyperoxaluria Type I.
Martin-Higueras C; Luis-Lima S; Salido E
Mol Ther; 2016 Apr; 24(4):719-25. PubMed ID: 26689264
[TBL] [Abstract][Full Text] [Related]
9. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Glycolate Oxidase With Dicer-substrate siRNA Reduces Calcium Oxalate Deposition in a Mouse Model of Primary Hyperoxaluria Type 1.
Dutta C; Avitahl-Curtis N; Pursell N; Larsson Cohen M; Holmes B; Diwanji R; Zhou W; Apponi L; Koser M; Ying B; Chen D; Shui X; Saxena U; Cyr WA; Shah A; Nazef N; Wang W; Abrams M; Dudek H; Salido E; Brown BD; Lai C
Mol Ther; 2016 Apr; 24(4):770-8. PubMed ID: 26758691
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria.
Forbes TA; Brown BD; Lai C
Br J Clin Pharmacol; 2022 Jun; 88(6):2525-2538. PubMed ID: 34022071
[TBL] [Abstract][Full Text] [Related]
12. Re: An Investigational RNAi Therapeutic Targeting Glycolate Oxidase Reduces Oxalate Production in Models of Primary Hyperoxaluria.
Assimos DG
J Urol; 2017 May; 197(5):1297-1298. PubMed ID: 29539912
[No Abstract] [Full Text] [Related]
13. Nephrocalcinosis can disappear in infants receiving early lumasiran therapy.
Kayal D; Sellier-Leclerc AL; Acquaviva-Bourdain C; de Mul A; Cabet S; Bacchetta J
Pediatr Nephrol; 2024 Jul; 39(7):2079-2082. PubMed ID: 38261066
[TBL] [Abstract][Full Text] [Related]
14. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
[TBL] [Abstract][Full Text] [Related]
15. Glycolate oxidase inhibition by lumasiran varies between patients with primary hyperoxaluria type 1.
Garrelfs SF; Metry EL; van Harskamp D; Vaz FM; van den Akker CHP; Schierbeek H; Groothoff JW; Oosterveld MJS
Kidney Int; 2023 May; 103(5):990-993. PubMed ID: 36871948
[No Abstract] [Full Text] [Related]
16. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Shah VN; Pyle L
N Engl J Med; 2021 Nov; 385(20):e69. PubMed ID: 34758264
[No Abstract] [Full Text] [Related]
17. Phase 3 trial of lumasiran for primary hyperoxaluria type 1: A new RNAi therapeutic in infants and young children.
Sas DJ; Magen D; Hayes W; Shasha-Lavsky H; Michael M; Schulte I; Sellier-Leclerc AL; Lu J; Seddighzadeh A; Habtemariam B; McGregor TL; Fujita KP; Frishberg Y;
Genet Med; 2022 Mar; 24(3):654-662. PubMed ID: 34906487
[TBL] [Abstract][Full Text] [Related]
18. Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1. Reply.
Garrelfs SF; Gansner JM; Lieske JC
N Engl J Med; 2021 Nov; 385(20):e69. PubMed ID: 34758265
[No Abstract] [Full Text] [Related]
19. Discovery of Novel, Potent Inhibitors of Hydroxy Acid Oxidase 1 (HAO1) Using DNA-Encoded Chemical Library Screening.
Lee ECY; McRiner AJ; Georgiadis KE; Liu J; Wang Z; Ferguson AD; Levin B; von Rechenberg M; Hupp CD; Monteiro MI; Keefe AD; Olszewski A; Eyermann CJ; Centrella P; Liu Y; Arora S; Cuozzo JW; Zhang Y; Clark MA; Huguet C; Kohlmann A
J Med Chem; 2021 May; 64(10):6730-6744. PubMed ID: 33955740
[TBL] [Abstract][Full Text] [Related]
20. CRISPR/Cas9-mediated glycolate oxidase disruption is an efficacious and safe treatment for primary hyperoxaluria type I.
Zabaleta N; Barberia M; Martin-Higueras C; Zapata-Linares N; Betancor I; Rodriguez S; Martinez-Turrillas R; Torella L; Vales A; Olagüe C; Vilas-Zornoza A; Castro-Labrador L; Lara-Astiaso D; Prosper F; Salido E; Gonzalez-Aseguinolaza G; Rodriguez-Madoz JR
Nat Commun; 2018 Dec; 9(1):5454. PubMed ID: 30575740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
